{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:11:43Z","timestamp":1785787903686,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.anai.2018.02.029","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T13:54:01Z","timestamp":1519739641000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Uses of biologics in allergic diseases"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0603-2797","authenticated-orcid":false,"given":"Tara Vinyette","family":"Saco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.02.029_bib0010","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2017.03.006","article-title":"Biologics and biomarkers for asthma, urticaria, and nasal polyposis","volume":"139","author":"Casale","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaip.2017.04.038","article-title":"Biologic therapy and novel molecular targets of severe asthma","volume":"5","author":"Pepper","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.029_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.anai.2016.05.016","article-title":"Characterization of asthma endotypes: implications for therapy","volume":"117","author":"Stokes","year":"2016","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt.13.118","article-title":"An update on biologic-based therapy in asthma","volume":"5","author":"Walsh","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.anai.2018.02.029_bib0035","doi-asserted-by":"crossref","first-page":"AB195","DOI":"10.1016\/j.jaci.2017.12.618","article-title":"Impact of baseline IgE levels on exacerbations and asthma symptom control after omalizumab initiation","volume":"141","author":"Casale","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0040","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.029_bib0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0055","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0060","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.anai.2018.02.029_bib0065","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0070","series-title":"Cochrane Database of Systematic Reviews","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014"},{"key":"10.1016\/j.anai.2018.02.029_bib0075","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/ACI.0000000000000012","article-title":"Biologic therapy for atopic asthma and beyond","volume":"13","author":"Caruso","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.iac.2017.01.007","article-title":"Biologic and new therapies in asthma","volume":"37","author":"Tabatabaian","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2018.02.029_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S29811","article-title":"Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting","volume":"5","author":"Ali","year":"2012","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anai.2018.02.029_bib0090","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0105","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.02.029_bib0115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2017.1316194","article-title":"Benralizumab for the treatment of asthma","volume":"13","author":"Saco","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0125","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.02.029_bib0130","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.02.029_bib0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0145","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.anai.2018.02.029_bib0155","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0160","article-title":"Monoclonal antibodies for treatment of eosinophilic esophagitis","author":"Eskian","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0165","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-018-8674-3","article-title":"Biological therapies for eosinophilic esophagitis: where do we stand","author":"Ko","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0175","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.anai.2018.02.029_bib0180","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0185","first-page":"A4678","article-title":"Benralizumab significantly reduced oral corticosteroid dosages and asthma exacerbation rates for patients with severe, uncontrolled asthma: results of the ZONDA phase III trial","volume":"195","author":"Nair","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"9","key":"10.1016\/j.anai.2018.02.029_bib0200","article-title":"Anti-IL5 therapies for asthma","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2018.02.029_bib0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.029_bib0215","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0220","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0230","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0235","article-title":"The XTEND-CIU study: long term use of omalizumab in chronic idiopathic urticaria","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0240","article-title":"Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND-CIU study","author":"Casale","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.02.029_bib0245","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00281-015-0491-7","article-title":"CAPS\u2013pathogenesis, presentation and treatment of an autoinflammatory disease","volume":"37","author":"Kuemmerle-Deschner","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.anai.2018.02.029_bib0250","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/imt.14.106","article-title":"The inflammasome and IL-1\u03b2: implications for the treatment of inflammatory diseases","volume":"7","author":"Satoh","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.anai.2018.02.029_bib0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0260","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.anai.2018.02.029_bib0265","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","article-title":"Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study","volume":"13","author":"N\u00e9el","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.anai.2018.02.029_bib0270","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0275","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0280","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaoto.2016.0678","article-title":"Subcutaneous dupilumab and mometasone furoate nasal spray for chronic rhinosinusitis with polyps","volume":"142","author":"Schneider","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anai.2018.02.029_bib0285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2018.02.029_bib0290","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jaip.2017.08.031","article-title":"Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines","volume":"5","author":"Boguniewicz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2018.02.029_bib0295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.anai.2018.02.029_bib0305","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0310","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0315","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.anai.2018.02.029_bib0320","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2018.02.029_bib0325","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.02.029_bib0330","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.029_bib0335","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:19:14Z","timestamp":1761052754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112061830156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S108112061830156X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.029","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uses of biologics in allergic diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}